With Stock Sale, Roche to Cut Its Genentech Stake
Genentech Inc., the world’s No. 2 biotechnology company, said Thursday that 17.3 million shares of its common stock are being offered by Roche Holding at $163 each, or about $2.82 billion worth of shares.
After the offering, Roche’s stake in Genentech would be reduced to about 58% from 66%. If an option for underwriters to purchase an additional 1.7 million shares isn’t exercised, Roche’s stake will be about 59%.
Genentech said it won’t receive proceeds from the offering. The closing of the transaction is expected Wednesday.
J.P. Morgan & Co., Goldman, Sachs & Co., Merrill Lynch & Co., Warburg Dillon Read, Lehman Brothers Inc. and Robertson Stephens are managing the stock offering.
South San Francisco-based Genentech fell $6.69 to close at $167.31 on the New York Stock Exchange.
The announcement was made after the close of regular U.S. trading.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
